8.30AM - 6.30PM EST | 5.30AM - 3.30PM PST

8:30 am Online Registration & Coffee Networking Session

8:50 am Chair’s Opening Remarks

Spotlight on Clinical Progress for Inflammasome Targeted Therapies

9:00 am Exploring Small Molecule Inflammasome Inhibitors in Retinal Disease

  • Paul Ashton Chief Executive Officer, Inflammasome Therapeutics

9:30 am Cell-Based Methods to Quantify Inflammasome Activation and Target Engagement

10:00 am Inhibiting the NLRP3 Inflammasome Activation Signal in Chronic Disease Through Connexin Hemichannel Modulation

  • Colin Green Co-founder & Chief Scientific Officer, OcuNexus Therapeutics

10:30 am Live Q&A

  • Paul Ashton Chief Executive Officer, Inflammasome Therapeutics
  • Martha O’Brien Senior Research Scientist, Promega Corporation
  • Colin Green Co-founder & Chief Scientific Officer, OcuNexus Therapeutics

Synopsis

Have the speakers answer your questions

10:50 am Morning Refreshments & Virtual Speed Networking

11:30 am

1:00 pm Lunch & Networking

2:00 pm

4:10 pm Inhibition of NLRP3 Expression by Exosome Delivery of Antisense Oligonucleotide (ASO)

  • Joanne Lim Senior Scientist, Cellular Immunology, Codiak Biosciences

4:20 pm Speed Networking & Afternoon Break

Exploring Novel Therapeutic Targets

4:50 pm Inflammasomes: Gatekeepers at the front line of skin health

  • Vincent Gruber Director of New Technology, JEEN International Corporation

5:20 pm Novel Approach to Identify & Validate Uric Acid-Driven Mediators of Inflammation

  • Scott Bowers Associate Director, Preclinical Pharmacology, Horizon Therapeutics

5:50 pm Live Q&A

  • Vincent Gruber Director of New Technology, JEEN International Corporation
  • Scott Bowers Associate Director, Preclinical Pharmacology, Horizon Therapeutics

Synopsis

Have the speaker answer your questions

6:10 pm Chair’s Closing Remarks